Review article: The patient with gastro-oesophageal reflux disease - Lifestyle advice and medication

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 8, 2004, Pages 24-27

  Holtmann, G ^a   Adam, B ^a   Liebregts, T ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ACID SECRETION; ADULT; AGED; CONFERENCE PAPER; ENVIRONMENTAL FACTOR; GASTROESOPHAGEAL REFLUX; GENETIC ANALYSIS; HUMAN; INFECTION RATE; LIFESTYLE; LOWER ESOPHAGUS SPHINCTER; MAJOR CLINICAL STUDY; NUTRITION; PREVALENCE; PRIORITY JOURNAL; SLEEP; SYMPTOMATOLOGY;

EID: 10644297053     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02224.x     Document Type: Conference Paper

References (33)

1. Sonnenberg A, El Serag HB. Clinical epidemiology and natural history of gastroesophageal reflux disease. Yale J Biol Med 1999; 72: 81-92.
2. Howard PJ, Heading RC. Epidemiology of gastro-esophageal reflux disease. World J Surg 1992; 16: 288-93.
3. Kay L, Jorgensen T, Jensen KH. Epidemiology of abdominal symptoms in a random population: prevalence, incidence, and natural history. Eur J Epidemiol 1994; 10: 559-66.
4. Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillierès Best Pract Res Clin Gastroenterol 2000; 14: 743-57.
5. Wienbeck M, Barnert J. Epidemiology of reflux disease and reflux esophagitis. Scand J Gastroenterol Suppl 1989; 156: 7-13.
6. Moss SF, Armstrong D, Arnold R, et al. GERD 2003 - a consensus on the way ahead. Digestion 2003; 67: 111-7.
7. Reynolds JC, Waronker M, Pacquing MS, Yassin RR. Barrett's esophagus. Reducing the risk of progression to adenocarcinoma. Gastroenterol Clin North Am 1999; 28: 917-45.
8. Terry P, Lagergren J, Wolk A, Nyren O. Reflux-inducing dietary factors and risk of adenocarcinoma of the esophagus and gastric cardia. Nutr Cancer 2000; 38: 186-91.
9. Newnham A, Quinn MJ, Babb P, Kang JY, Majeed A. Trends in the subsite and morphology of oesophageal and gastric cancer in England and Wales 1971-98. Aliment Pharmacol Ther 2003; 17: 665-76.
10. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-9.
11. Ruhl CE, Everhart JE. Overweight, but not high dietary fat intake, increases risk of gastroesophageal reflux disease hospitalization: the NHANES I Epidemiologic Follow-up Study. First National Health and Nutrition Examination Survey. Ann Epidemiol 1999; 9: 424-35.
12. Nilsson M, Johnsen RYeW, Hveem K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 2003; 290: 66-72.
13. Graham DY. Changing patterns of peptic ulcer, gastro-oesophageal reflux disease and Helicobacter pylori: a unifying hypothesis. Eur J Gastroenterol Hepatol 2003; 15: 571-2.
14. Fallone CA, Barkun ANH. pylori-infected gastroesophageal reflux disease patients harbor less virulent strains. Am J Gastroenterol 2002; 97: 1065.
15. Loffeld RJ, Werdmuller BF, Kuster JG, Perez-Perez GI, Blaser MJ, Kuipers EJ. Colonization with cagA-positive Helicobacter pylori strains inversely associated with reflux esophagitis and Barrett's esophagus. Digestion 2000; 62: 95-9.
16. Vaezi MF, Falk GW, Peek RM, et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000; 95: 2206-11.
17. Vicari JJ, Peek RM, Falk GW, et al. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998; 115: 50-7.
18. Kiltz U, Pfaffenbach B, Schmidt WE, Adamek RJ. The lack of influence of CagA positive Helicobacter pylori strains on gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol 2002; 14: 979-84.
19. Oberg S, Peters JH, Nigro JJ, et al. Helicobacter pylori is not associated with the manifestations of gastroesophageal reflux disease. Arch Surg 1999; 134: 722-6.
20. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-6.
21. Feinle C, Christen M, Grundy D, et al. Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil 2002; 14: 205-13.
22. Cecil JE, Francis J, Read NW. Comparison of the effects of a high-fat and high-carbohydrate soup delivered orally and intragastrically on gastric emptying, appetite, and eating behaviour. Physiol Behav 1999; 67: 299-306.
23. Becker DJ, Sinclair J, Castell DO, Wu WC. A comparison of high and low fat meals on postprandial esophageal acid exposure. Am J Gastroenterol 1989; 84: 782-6.
24. Rubinstein E, Hauge C, Sommer P, Mortensen T. Oesophageal and gastric potential difference and pH in healthy volunteers following intake of coca-cola, red wine, and alcohol. Pharmacol Toxicol 1993; 72: 61-5.
25. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002; 16: 479-85.
26. Collings KL, Pierce PF, Rodriguez-Stanley S, Bemben M, Miner PB. Esophageal reflux in conditioned runners, cyclists, and weightlifters. Med Sci Sports Exerc 2003; 35: 730-5.
27. Yancy WS Jr, Provenzale D, Westman EC. Improvement of gastroesophageal reflux disease after initiation of a low-carbohydrate diet: five brief case reports. Altern Ther Health Med 2001; 7: 116-9.
28. Pollmann H, Zillessen E, Pohl J, et al. Effect of elevated head position in bed in therapy of gastroesophageal reflux. Z Gastroenterol 1996; 34 (Suppl. 2): 93-9.
29. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci 1981; 26: 673-80.
30. Vigneri S, Termini R, Leandro G, et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Med 1995; 333: 1106-10.
31. Furuta T, Shirai N, Watanabe F, et al. Effect of cytochrome P4502C19 genotypic differences on cure rates for gastroesophageal reflux disease by lansoprazole. Clin Pharmacol Ther 2002; 72: 453-60.
32. Kawamura M, Ohara S, Koike T, et al. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism. Aliment Pharmacol Ther 2003; 17: 965-73.
33. Sagar M, Bertilsson L, Stridsberg M, Kjellin A, Mardh S, Seensalu R. Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders. Aliment Pharmacol Ther 2000; 14: 1495-502.